

Another embodiment pertains to a method of treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment, said method comprising administering to the subject therapeutically effective amount of the compound of this invention and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

Another embodiment pertains to a composition for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of a compound as disclosed herein.

Another embodiment pertains to the use of a therapeutically effective amount of a compound as disclosed herein in the manufacture of a medicament for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a subject in need of treatment.

Another embodiment pertains to the use of a therapeutically effective amount of the compound as disclosed herein and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent in the manufacture of a medicament for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a subject in need of treatment.

Another embodiment pertains to a composition for use in treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome, said composition comprising an excipient and a therapeutically effective amount of a compound as disclosed herein.

Another embodiment pertains to the use of a therapeutically effective amount of a compound as disclosed herein in the manufacture of a medicament for treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment.

Another embodiment pertains to the use of a therapeutically effective amount of the compound as disclosed herein and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent in the manufacture of a medicament for treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes" and "included", is not limiting. With reference to the use of the words "comprise" or "comprises" or "comprising" in this patent application (including the claims), Applicants note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that Applicants intend each of those words to be so interpreted in construing this patent application, including the claims below. For a variable that occurs more than one time in any substituent or in the compound of the invention or any other formulae herein, its definition on each occurrence is independent of its definition at every other occurrence. Combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds which can be isolated in a useful degree of purity from a reaction mixture.

The terms "treat", "treating" and "treatment" refer to a method of alleviating or abrogating a disease and/or its attendant symptoms.

The terms "prevent", "preventing" and "prevention" refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, "prevent", "preventing" and "prevention" also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.

and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.

170 | 2. A composition for use in treating bladder cancer, brain cancer, breast cancer, bone
marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer,
esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma,
lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia,
175 | leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said
composition comprising an excipient and a therapeutically effective amount of a
compound of claim 1.

180 | 3. ~~A method of~~ Use of a therapeutically effective amount of a compound of claim 1
in the manufacture of a medicament for treating bladder cancer, brain cancer, breast
cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal
cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular
lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous
185 | leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic
lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer
in a subject in need of treatment, ~~said method comprising administering to the subject a~~
~~therapeutically effective amount of a compound of claim 1.~~

190 | 4. ~~A method of~~ Use of a therapeutically effective amount of the compound of claim
1 and a therapeutically effective amount of one additional therapeutic agent or more than
one additional therapeutic agent in the manufacture of a medicament for treating bladder
cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic
lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer,
lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell
195 | origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer,
non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer,
small cell lung cancer or spleen cancer in a subject in need of treatment, ~~said method~~
~~comprising administering to the subject therapeutically effective amount of the compound~~
~~of claim 1 and a therapeutically effective amount of one additional therapeutic agent or~~
200 | ~~more than one additional therapeutic agent.~~

5. A composition for use in treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome, said composition comprising an excipient and a therapeutically effective amount of a compound of claim 1.

205

6. ~~A method of treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment, said method comprising administering to the subject~~ Use of a therapeutically effective amount of a compound of claim 1 in the manufacture of a medicament for treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment.

210

7. ~~A method of treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment, said method comprising administering to the subject~~ Use of a therapeutically effective amount of the compound of claim 1 and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent in the manufacture of a medicament for treating systemic lupus erythematosus, lupus nephritis, or Sjogren's Syndrome in a subject in need of treatment.

215

220